While respiratory syncytial virus (RSV) typically causes mild symptoms in adults, the virus can be life-threatening for infants. The seasonal virus is the most common cause of lower respiratory tract ...

Research shows RSV leads to high hospitalization rates in adults, emphasizing the importance of enhanced surveillance and ...

Shares of Moderna MRNA rose nearly 6% yesterday after the U.S. Centers for Disease Control and Prevention (“CDC”) adopted new ...

Researchers found that older adults who received AS01-adjuvanted shingles or RSV vaccines had a significantly lower risk of ...

Taking aim at a longtime target of anti-vaccine activists, CDC advisors said Thursday that the U.S. should not administer ...

Vietnam trade deal helps support fresh record highs: Both the S&P 500 and Nasdaq pushed to new closing highs, in part thanks ...

The advisory panel first voted, with one abstention, to back the usual U.S. recommendation that nearly everyone age 6 months ...

A newly configured federal vaccine panel's June 25 action is expected to improve options to protect infants from potentially ...

The recommendation for Enflonsia is indicated for respiratory syncytial virus prevention in infants under eight months of age, expanding protection options ahead of the 2025–2026 season.

Members of the Infectious Disease Society of America highlighted clinical implications in wake of the ACIP meeting.

The Trump administration appears to be expanding RSV vaccinations to some adults starting at age 50, down from 60, following the advice of a recently fired panel of government vaccine advisers. The de ...